ClaudiaA.ChiribogaMD

Neuromuscular Medicine

MD, MPH Columbia Presbyterian Medical Center

Overview of Dr. Chiriboga

Dr. Claudia Chiriboga is a Child Neurologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Columbia University Irving Medical Center and Morgan Stanley Childrens Hospital of NewYork-Presbyterian. She received her medical degree from University of Buenos Aires and has been in practice 38 years. She is one of 24 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 10 doctors at Morgan Stanley Childrens Hospital of NewYork-Presbyterian who specialize in Child Neurology. She has more than 50 publications and over 500 citings.

Office
180 Fort Washington Avenue
New York, NY 10032
Book by Phone+1(234) 720-3090

Education & Training

Icahn School of Medicine at Mount SinaiResidency, Pediatrics, 1982 - 1985
University of Buenos AiresClass of 1982

Certifications & Licensure

NJ State Medical License Current
NY State Medical License 1985 - 2026
MD State Medical License 1984 - 1986
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology

Publications & Presentations

PubMed

JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri
Journal of Neurology. 2024-08-01
3 citations
Digital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-b...
Thanneer Malai Perumal, Detlef Wolf, Doris Berchtold, Grégoire Pointeau, Yan-Ping Zhang
Neuromuscular Disorders. 2023-11-01
1 citations
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri
Neurology and Therapy. 2023-10-01

Press Mentions

Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients with Previously-Treated Spinal Muscular Atrophy (SMA)October 12th, 2022
New Genentech Data for Evrysdi (Risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with Spinal Muscular Atrophy (SMA)June 11th, 2021